TrialThe Journal of infectious diseases2022

Safety and Antiviral Effects of Nebulized PC786 in a Respiratory Syncytial Virus Challenge Study.

John DeVincenzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.